Arcutis Biotherapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
06/05/2025 22:02
Arcutis Biotherapeutics Inc ARQT.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -32 cents. The mean expectation of seven analysts for the quarter was for a loss of 21 cents per share. Wall Street expected results to range from -27 cents to -15 cents per share. Revenue rose 32.8% to $65.85 million from a year ago; analysts expected $62.25 million. Arcutis Biotherapeutics Inc's reported EPS for the quarter was a loss of 20 cents. The company reported a quarterly loss of $25.06 million. Arcutis Biotherapeutics Inc shares had fallen by 1.5% this quarter and gained 10.6% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 25.9% in the last three months. In the last 30 days, one analyst negatively revised an earnings estimate RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" Wall Street's median 12-month price target for Arcutis Biotherapeutics Inc is $20.00 This summary was machine generated from LSEG data May 6 at 09:02 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Mar. 31 2025 | -0.21 | -0.20 | Beat |
| Dec. 31 2024 | -0.25 | -0.09 | Beat |
| Sep. 30 2024 | -0.42 | -0.33 | Beat |
| Jun. 30 2024 | -0.52 | -0.42 | Beat |
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf